# A Study to Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese Volunteers

> **NCT06527755** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 12 (actual)

## Conditions studied

- Transthyretin-mediated Amyloidosis

## Interventions

- **DRUG:** Eplontersen Solution for Injection

## Key facts

- **NCT ID:** NCT06527755
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-06
- **Primary completion:** 2024-09-11
- **Final completion:** 2024-11-15
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06527755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06527755, "A Study to Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese Volunteers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06527755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*